198.04p+0.84 (+0.43%)28 Mar 2024, 14:33
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Oxford Biomedica PLC Fundamentals

Company NameOxford Biomedica PLCLast Updated2024-03-28
IndustryBiotechnologySectorHealthcare
Shares in Issue99.957 mMarket Cap£197.96 m
PE Ratio20.62Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.41EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.2821Debt Equity Ratio0.6361
Asset Equity Ratio2.0240Cash Equity Ratio0.6533
Quick Ratio2.8548Current Ratio3.32
Price To Book Value1.1453ROCE0

Oxford Biomedica PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Oxford Biomedica PLC Company Financials

Assets20222021
Tangible Assets£133.78 m£69.73 m
Intangible Assets£105.89 m£52,000.00
Investments00
Total Fixed Assets£244.68 m£73.39 m
Stocks£12.63 m£9.52 m
Debtors£49.84 m£36.31 m
Cash & Equivalents£141.31 m£109.02 m
Other Assets£5.01 m£3.60 m
Total Assets£460.18 m£237.23 m
Liabilities20222021
Creditors within 1 year£59.66 m£33.31 m
Creditors after 1 year£164.32 m£16.58 m
Other Liabilities00
Total Liabilities£223.99 m£49.89 m
Net assets£236.19 m£187.34 m
Equity20222021
Called up share capital£48.13 m£43.09 m
Share Premium£379.95 m£307.76 m
Profit / Loss-£45.98 m£19.88 m
Other Equity£204.65 m£187.34 m
Preference & Minorities£31.54 m0
Total Capital Employed£236.19 m£187.34 m
Ratios20222021
Debt Ratio£0.35£0.04
Debt-to-Equity£0.54£0.05
Assets / Equity2.02402.0240
Cash / Equity0.65330.6533
EPS-£0.41£0.23
Cash Flow20222021
Cash from operating activities-£12.62 m£25.45 m
Cashflow before financing£86.01 m£71.66 m
Increase in Cash£29.55 m£62.20 m
Income20222021
Turnover£139.99 m£142.80 m
Cost of sales£70.81 m£60.16 m
Gross Profit£69.18 m£82.64 m
Operating Profit-£30.22 m£20.77 m
Pre-Tax profit-£45.98 m£19.88 m

Oxford Biomedica PLC Company Background

SectorHealthcare
ActivitiesOxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focuses on the field of immunotherapy by managing a platform of technologies for designing gene-based medicines. The company's operating segments include the Platform segment consists of the revenue-generating bioprocessing and process development activities undertaken for third parties. Its Product segment consists of the clinical and preclinical development of in vivo and ex vivo gene and cell therapy products. The company derives the maximum revenue from the Platform segment. Its Platform includes LentiVector, LentiStable, TRiPSystem, SecNuc, Analytics, and others. Geographically, it generates the majority of its revenue from Europe.
Latest Interim Date20 Sep 2023
Latest Fiscal Year End Date25 Apr 2023

Oxford Biomedica PLC Directors

AppointedNamePosition
2012-04-30Mr. Andrew Brian WoodExecutive Director,Chief Financial Officer and Company Sec
2020-06-23Dr. Lorenzo Tallarigo, M.D.Non-Executive Director,Chairman
2016-01-05Mr. Daniel B. Soland Non-Executive Director
2023-09-26Ms. Leone D Patterson
2013-06-06Dr. Stuart NaylorExecutive Director,Chief Scientific Officer
2022-05-27Mr. John Andrew Dawson CBEExecutive Director,Chief Executive Officer
2011-01-10Dr. Alexander D LewisNon-Executive Director
2022-04-27Dr. Andrew John William HeathNon-Executive Director
2020-06-08Professor Alan John KingsmanNon-Executive Director,Chairman
2017-04-28Dr. Paul BlakeExecutive Director,Chief Development Officer
2018-06-29Mr. Peter J NolanExecutive Director,Chief Business Officer
2016-04-30Mr. Philip Nicholas RodgersNon-Executive Director
2011-08-09Mr. Nick WoolfInvestor Relation
2011-08-09Dr. Michael McDonaldExecutive Director,Chief Executive Officer
2023-09-20Dr. Roch F. DoliveuxNon-Executive Director,Chairman
2023-11-16Dr. Michael Hayden, Ch.B.,M.B.,PhDNon-Executive Director
2011-08-09Dr. Peter Johnson BSc,PhD,FRSC,FIBiol,FRCPathNon-Executive Director,Chairman
2011-08-09Professor Susan Mary Kingsman, M.A.,PhDExecutive Director
2018-04-26Mr. Timothy William Watts Non-Executive Director
2021-02-03Mr. Martin Henry Diggle Non-Executive Director
2023-10-04Dr. Frank MathiasExecutive Director,Chief Executive Officer
2023-07-03Dr. Heather Elizabeth PrestonNon-Executive Director
2023-09-20Mr. Stuart HendersonNon-Executive Director,Vice Chairman
2023-10-04Mr. Stuart PaynterExecutive Director,Chief Financial Officer
2023-09-20Ms. Catherine MoukheibirNon-Executive Director
2023-04-28Dr. Siyamak RastyNon-Executive Director
2023-09-26Professor Dame Kay DaviesNon-Executive Director,Senior Independent Director
2023-10-11Ms. Namrata P PatelNon-Executive Director

Oxford Biomedica PLC Contact Details

Company NameOxford BioMedica PLC
AddressWindrush Court, Transport Way, Oxford, OX4 6LT
Telephone+44 1865783000
Websitehttps://www.oxb.com

Oxford Biomedica PLC Advisors

StockbrokerWG Partners
Financial AdviserPeel Hunt LLP
Phone+44 2074188900
StockbrokerPeel Hunt LLP
Phone+44 2074188900
Remuneration ConsultantDeloitte LLP
Phone+44 2079363000
Fax+44 2075831198
Financial AdviserWG Partners LLP
Financial PR AdviserConsilium Strategic Communications
Phone+44 2037095700
BankBarclays Bank PLC
RegistrarLink Asset Services
Phone+44 8716640300
Fax+44 2086392342
SolicitorCovington & Burling LLP
Phone+44 2070672000
Fax +44 2070672222